Press release
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Outlook: Advancing Research and Growing Awareness to Shape the Landscape by 2034 | Says DelveInsight
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare and progressive form of glomerular disease marked by immune complex deposition and complement activation, leading to chronic kidney damage. Often presenting with proteinuria, hematuria, and declining renal function, IC-MPGN poses diagnostic and therapeutic challenges due to its heterogeneous nature and overlapping features with other kidney disorders.Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare and progressive form of glomerular disease marked by immune complex deposition and complement activation, leading to chronic kidney damage. Often presenting with proteinuria, hematuria, and declining renal function, IC-MPGN poses diagnostic and therapeutic challenges due to its heterogeneous nature and overlapping features with other kidney disorders.
DelveInsight's "IC-MPGN - Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" delivers a deep dive analysis of the evolving disease landscape, highlighting epidemiological patterns across major geographies such as the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores current diagnostic criteria, clinical management practices, and the ongoing shift towards precision nephrology.
Despite the limited availability of disease-specific therapies, ongoing research into the role of complement pathways and immune modulation is opening new therapeutic avenues. The IC-MPGN market is expected to witness steady progress fueled by improved diagnostic tools, patient registry expansion, and a growing pipeline of targeted treatments. This report offers essential insights for nephrologists, researchers, biopharma stakeholders, and decision-makers aiming to navigate this complex and underserved renal condition.
Some of the Key Facts of the Immune Complex Membranoproliferative Glomerulonephritis Market Report:
- The IC-MPGN market in the 7MM is expected to grow at a notable CAGR from 2023 to 2034.
- In 2023, the U.S. market size for IC-MPGN was approximately USD 12 million, projected to rise by 2034 due to increasing diagnosed prevalence and the launch of high-cost emerging therapies.
- The total diagnosed prevalent population of IC-MPGN in the 7MM was around 7,100 cases in 2023, with the United States accounting for roughly 55% (~3,770 cases), followed by Japan.
- Among the EU4 and the UK, Germany had the highest number of diagnosed cases in 2023, followed by Spain, while Italy had the fewest.
- In 2023, males accounted for approximately 52% of all diagnosed IC-MPGN cases in the United States.
- In April 2025, the FDA granted Priority Review to pegcetacoplan (Empaveli), a C3/C3b inhibitor, for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This designation is given to therapies for serious conditions that, if approved, offer significant improvements in treatment or outcomes.
- In March 2025, the FDA approved Fabhalta (iptacopan) by Novartis as the first authorized treatment for C3 glomerulopathy (C3G) in adults, offering a new option to reduce proteinuria in this rare kidney disease.
- Leading companies in the immune complex membranoproliferative glomerulonephritis market include Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
- Emerging acute immune complex membranoproliferative glomerulonephritis drugs include Iptacopan (LNP023), Pegcetacoplan (APL-2), and others.
- The rising incidence of immune complex membranoproliferative glomerulonephritis (iC-MPGN), coupled with ongoing advancements in diagnostic precision and therapeutic innovation, is fueling the need for more targeted and effective treatment strategies.
To know in detail about the immune complex membranoproliferative glomerulonephritis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Immune Complex Membranoproliferative Glomerulonephritis Market Forecast [https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Immune Complex Membranoproliferative Glomerulonephritis Overview
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare, progressive kidney disorder characterized by the deposition of immune complexes in the glomeruli, leading to chronic inflammation and injury. It primarily affects children and young adults, though it can occur at any age. IC-MPGN is marked histologically by mesangial cell proliferation and thickening of the glomerular basement membrane. Patients often present with symptoms such as proteinuria, hematuria, hypertension, and declining renal function. If left unmanaged, IC-MPGN can progress to end-stage renal disease (ESRD), requiring dialysis or transplantation.
The pathogenesis of IC-MPGN is complex and often associated with chronic infections, autoimmune diseases, or monoclonal gammopathy. Diagnosis typically relies on kidney biopsy, immunofluorescence, and complement studies to distinguish it from other forms of MPGN. Despite advancements in nephrology, treatment remains challenging due to limited targeted therapies. Current management involves immunosuppressive agents, RAAS inhibitors, and supportive care. However, with a growing understanding of complement dysregulation and immune mechanisms, new therapies are being explored, making the IC-MPGN landscape an area of active clinical and research interest.
Get a free sample of the Immune complex membranoproliferative glomerulonephritis market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market [https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Immune Complex Membranoproliferative Glomerulonephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation:
The Immune Complex Membranoproliferative Glomerulonephritis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
- Total Incident Cases of IC-MPGN
- Total Gender-specific Cases of IC-MPGN
- Total Region-specific Cases of IC-MPGN
- Total Treated Cases of IC-MPGN
Download the report to understand which factors are driving immune complex membranoproliferative glomerulonephritis epidemiology trends @ Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Forecast [https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Immune Complex Membranoproliferative Glomerulonephritis Drugs Uptake and Pipeline Development Activities
The immune complex membranoproliferative glomerulonephritis drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the immune complex membranoproliferative glomerulonephritis market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the immune complex membranoproliferative glomerulonephritis pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Immune Complex Membranoproliferative Glomerulonephritis Market Outlook
The treatment landscape for Immune Complex-Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) remains largely underserved, with no approved therapies currently available. Most patients rely on off-label immunosuppressants, RAAS inhibitors, and supportive treatments, which offer only limited benefit in slowing disease progression. Given the disease's association with complement pathway dysregulation, targeted complement inhibition presents a promising therapeutic avenue.
The market is gradually evolving, fueled by growing awareness of the disease's pathophysiology and a push for more precise treatments. Notably, two potential therapies-Iptacopan (Novartis Pharmaceuticals) and Pegcetacoplan (Apellis Pharmaceuticals)-have reached Phase III trials, signaling progress toward more effective, disease-modifying interventions. As research advances and clinical trials mature, the IC-MPGN market is poised for transformation, offering hope to patients facing a high risk of kidney failure and limited treatment options.
Immune Complex Membranoproliferative Glomerulonephritis Market Strengths
- The development of novel complement inhibitors such as Iptacopan and Pegcetacoplan in Phase III trials marks a promising shift toward disease-specific treatment, addressing the core pathophysiology of IC-MPGN.
- Growing awareness among nephrologists and researchers about complement dysregulation in IC-MPGN is driving both diagnostic improvements and investment in specialized therapeutic approaches.
Immune Complex Membranoproliferative Glomerulonephritis Market Weaknesses
- The absence of any FDA or EMA-approved treatments for IC-MPGN leaves patients reliant on off-label and largely ineffective immunosuppressive regimens, contributing to poor long-term outcomes.
- As an ultra-rare disease, IC-MPGN faces challenges related to low prevalence, limited clinical trial enrollment, and sparse real-world evidence, which can hinder drug development and commercialization efforts.
Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report
- Study Period: 2020-2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Immune Complex Membranoproliferative Glomerulonephritis Companies: Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others.
- Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: Iptacopan (LNP023), Pegcetacoplan (APL-2), and others.
- Immune Complex Membranoproliferative Glomerulonephritis Therapeutic Assessment: Immune Complex Membranoproliferative Glomerulonephritis, currently marketed, and Immune Complex Membranoproliferative Glomerulonephritis emerging therapies
- Immune Complex Membranoproliferative Glomerulonephritis Market Dynamics: Immune Complex Membranoproliferative Glomerulonephritis market drivers and Immune Complex Membranoproliferative Glomerulonephritis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs, KOL's views, Analyst's views, Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement
To learn more about the key players and advancements in the Immune Complex Membranoproliferative Glomerulonephritis treatment landscape, visit the Immune Complex Membranoproliferative Glomerulonephritis Market Analysis Report [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Table of Contents
1. Immune Complex Membranoproliferative Glomerulonephritis Market Report Introduction
2. Executive Summary for Immune Complex Membranoproliferative Glomerulonephritis
3. SWOT analysis of Immune Complex Membranoproliferative Glomerulonephritis
4. Immune Complex Membranoproliferative Glomerulonephritis Patient Share (%) Overview at a Glance
5. Immune Complex Membranoproliferative Glomerulonephritis Market Overview at a Glance
6. Immune Complex Membranoproliferative Glomerulonephritis Disease Background and Overview
7. Immune Complex Membranoproliferative Glomerulonephritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Immune Complex Membranoproliferative Glomerulonephritis
9. Immune Complex Membranoproliferative Glomerulonephritis Current Treatment and Medical Practices
10. Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs
11. Immune Complex Membranoproliferative Glomerulonephritis Emerging Therapies
12. Immune Complex Membranoproliferative Glomerulonephritis Market Outlook
13. Country-Wise Immune Complex Membranoproliferative Glomerulonephritis Market Analysis (2020-2034)
14. Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement of Therapies
15. Immune Complex Membranoproliferative Glomerulonephritis Market Drivers
16. Immune Complex Membranoproliferative Glomerulonephritis Market Barriers
17. Immune Complex Membranoproliferative Glomerulonephritis Appendix
18. Immune Complex Membranoproliferative Glomerulonephritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-complex-membranoproliferative-glomerulonephritis-icmpgn-market-outlook-advancing-research-and-growing-awareness-to-shape-the-landscape-by-2034-says-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Outlook: Advancing Research and Growing Awareness to Shape the Landscape by 2034 | Says DelveInsight here
News-ID: 4069166 • Views: …
More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…

Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…

Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…

Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Immune
Immune Probiotic Supplement Market Reviews: What Works Best for Gut and Immune S …
The Global Immune Probiotic Supplement Market reached US$ 68.73 Billion in 2024 and is projected to witness lucrative growth by reaching up to US$ 133.08 Billion by 2032. The Global Immune Probiotic Supplement Market is expected to exhibit a CAGR of 8.61% during the forecast period 2024-2032.
Immune Probiotic Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges.…
Decoding the Immune System: Immune Repertoire Sequencing Market Unleashes Insigh …
The Immune Repertoire Sequencing Market is likely to grow voraciously, i.e. at a CAGR of 7.3% between 2018-2026. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.
Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing…
Immune health supplement Market - Guardian of health: Supporting immune strength …
Newark, New Castle, USA: The "Immune health supplement Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Immune health supplement Market: https://www.growthplusreports.com/report/immune-health-supplement-market/7978
This latest report researches the industry structure,…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports.
Immune Health Supplements refer to the product which could improve human immune health.
The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
Learn more Through Sample Report…